The FDA is approving more drugs for rare diseases each year than ever before.

When politics, climate change or international conflicts have me down, I turn to biotech instead. There’s always a new scientific discovery, a new drug for a rare disease, a new medical device for a common ailment.

But non-industry media under-reports good news in biotech. Many biomedical stories that do go mainstream are inaccurate.

Here are ten real biomedical wins from 2018 (with a contentious #10):

  1. Alnylam* won approval for the first drug that uses RNAi, a new modality to silence mutations that cause genetic diseases like hATTR amyloidosis.

So whatever else happened in 2018, the biomedical endeavor continues its steady progress, to the benefit of us all.

—NBH

*Disclosure: I’ve owned shares in starred companies within the past 12 months.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.

Principal at RA Capital, on the boards of 7 biotech companies. Founder/CEO of Nivien Therapeutics. Australian-American. 50 countries and counting.